Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Xenetic Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XBIO
Nasdaq
8731
https://www.xeneticbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Xenetic Biosciences Inc
Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 24th, 2024 1:38 pm
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
- Mar 22nd, 2024 12:00 pm
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Jan 17th, 2024 2:00 pm
Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation
- Nov 30th, 2023 10:04 am
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
- Nov 10th, 2023 1:35 pm
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
- Oct 11th, 2023 1:05 pm
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:05 pm
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
- Aug 11th, 2023 1:25 pm
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
- Aug 11th, 2023 12:05 pm
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
- Aug 10th, 2023 9:30 pm
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Jul 13th, 2023 4:00 pm
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
- Jul 5th, 2023 12:45 pm
Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth Plans
- May 15th, 2023 12:08 pm
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
- May 12th, 2023 4:30 pm
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- May 11th, 2023 8:30 pm
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
- May 4th, 2023 12:35 pm
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
- May 3rd, 2023 12:35 pm
Scroll